Advanced searches left 3/3

Bromocriptine - PubMed

Summarized by Plex Scholar
Last Updated: 28 July 2022

* If you want to update the article please login/register

Effects of Bromocriptine on Glucose and Insulin Dynamics in Normal and Insulin Dysregulated Horses.

Before and after 14 days of therapy, horses underwent a combined glucose-insulin tolerance test to determine insulin sensitivity and a feeding challenge was used to analyze postprandial glycemic and insulin responses. Compared to non-ID horses, ID horses had elevated basal plasma levels of insulin and triglycerides, as well as lower adiponectin concentrations. ID horses had slower glucose clearance rates, which resulted in a longer period in positive phase and elevated insulin levels at 75 min compared to non-ID horses, according to the CGIT response curve. In non-ID versus ID horses, glucose and insulin responses to the feeding challenge were lower than those in ID horses. In all horses, Bromocriptine therapy reduced plasma prolactin and cholesterol, as well as elevated adiponectin levels. In all horses, the postprandial glycemic and insulinemic response following the oats meal was lower after bromocriptine therapy. These findings show that EA's physiological responses in horses may be different in horses than those in other species.

Source link: https://doi.org/10.3389/fvets.2022.889888


Bromocriptine therapy: Review of mechanism of action, safety and tolerability.

Bromocriptine, a sympatholytic dopamine D2 receptor agonist with remarkable bioactivity, is a sympatholytic dopamine D2 receptor agonist with high bioactivities. Bromocriptine long-term treatment has no or no adverse effects on renal, hepatic, cardiac, or hematologic functions. Bromocriptine is an effective and safe alternative for hyperprolactinemia-associated conditions, acromegaly, parkinsonism, type 2 diabetes mellitus, and several other disorders in a variety of dosage forms for optimal therapeutic results. As monotherapy or in combination with other medications, it seemed to be an innovative and safe addition to the pharmacopoeia of drugs used for the treatment of a wide range of diseases.

Source link: https://doi.org/10.1111/1440-1681.13678


The effects of combined bromocriptine and Bu-shen-zhu-yun decoction on serum hormones, anxiety, and pregnancy in hyperprolactinemic infertility patients.

Prolactin is a protein hormone secretly secreted by the anterior pituitary gland that regulates pituitary hormones. Traditional Chinese medicine has no side effects and positive results for many years of study. TCM and Western medicine therapy can both enhance treatment success and increase long-term prognosis in HPRL.

Source link: https://doi.org/10.21037/apm-21-3111


The therapeutic effect of bromocriptine as mesylate and estradiol valerate on serum and blood biochemistry of common quails.

We wanted to find Steroid safety in birds by ex-situ experiments in standard therapeutic doses. Each study group was based on 5 control group birds and 20 experimental group birds, with two trials scheduled over the summer and winter. The following two organizations representing two separate steroids trial groups were treated with therapeutic doses for the duration of 5, 10, 15, and 20 per season. Bromocriptine's hematological effects in most trials resulted in an rise in red blood cell count and white blood cell count, as mesylate's. On the other hand, steroid estradiol valerate decreased by a decrease in these parameters. The overall effect of steroids on the bird's serum and biochemistry of quails was similar, but not so different in terms of intensity, although not so different.

Source link: https://doi.org/10.1016/j.psj.2021.101552


Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis.

Peripartum cardiomyopathy is a rare but potentially life-threatening form of heart disease. We included reviews comparing the results of PPCM with or without bromocriptine use. At a 6-month follow-up, composite major adverse events were defined by a combination of death, the need for advanced HF therapies, persistent New York Heart Association functional class III/V, or left ventricular ejection percentage u2264 35%. The LVEF revival was characterized by LVEF's rise to more than 50%. Five93 PPCM patients were included in eight studies. Baseline LVEF was not significantly different between the two groups, with Baseline LVEF not significantly different between the groups. There was no significant relationship between bromocriptine use and lower composite major adverse events or LVEF recovery, according to the study. In conclusion, bromocriptine addition to standard HF therapy in PPCM was associated with increased longevity and improved LVEF improvement. No association was found between lower composite adverse clinical events or LVEF recovery.

Source link: https://doi.org/10.1007/s10741-021-10185-8

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions